Evidence map›Paper›PMID 20180606›Full record

Trial reportPharmacotherapy2010

Deterioration of blood pressure control after discontinuation of a physician-pharmacist collaborative intervention.

Barry L Carter, William R Doucette, Carrie L Franciscus, Gail Ardery, Karen M Kluesner, Elizabeth A Chrischilles

Abstract readComparative StudyMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Pharmacotherapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. 2011 Canadian Hypertension Education Program recommendations: an annual update.Canadian family physician Medecin de famille canadien · 2011
    Guideline
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Review
  15. Article
  16. Alcohol and prescription drug safety in older adults.Drug, healthcare and patient safety · 2013
    Article
  17. Review
  18. Sustained blood pressure control following discontinuation of a pharmacist intervention.Journal of clinical hypertension (Greenwich, Conn.) · 2011
    Article
  19. Article
  20. Hypertension Canada's 2020 hypertension guidelines for pharmacists: An update.Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Barry L CarterDepartment of Pharmacy Practice and Science, College of Pharmacy, University of Iowa, Iowa City, Iowa 52242, USA. barry-carter@uiowa.edu
William R Doucette
Carrie L Franciscus
Gail Ardery
Karen M Kluesner
Elizabeth A Chrischilles

Funding

University of Iowa Older Adults CERTU18HS016094 · AHRQ · UNIVERSITY OF IOWA · PI CHRISCHILLES, ELIZABETH A · 2006 to 2010
$4.0M
Collaborative Management of HypertensionR01HL069801 · NHLBI · UNIVERSITY OF IOWA · PI CARTER, BARRY L · 2003 to 2005
$2.0M
AHRQ HHS U18 HS016094NHLBI NIH HHS R01 HL069801NHLBI NIH HHS R01 HL69801PHS HHS 5U18HSO16094
6 · The paper itself

Abstract

STUDY

objectiveTo assess blood pressure control after discontinuation of a physician-pharmacist collaborative intervention.

designComparative analysis of data of the patients who received the intervention versus a control group from a prospective, cluster-randomized, 9-month efficacy trial and the same patients' data 18 and 27 months after completion of the trial, abstracted from their medical records.

settingFive primary care medical offices operated by a university health system. PATIENTS: One hundred four patients with hypertension; 65 were in the intervention group, and 39 were in the control group. MEASUREMENTS AND MAIN

resultsIn the prospective study, patients were randomized to receive a physician-pharmacist collaborative intervention to improve blood pressure control or to the control group. Systolic and diastolic blood pressures were measured by a research nurse at baseline and at the end of the study (9 mo later). In the current study, data were abstracted for blood pressure and blood pressure control at 18 and 27 months (9 and 18 mo, respectively, after discontinuation of the study). At baseline, mean +/- SD systolic blood pressure was 152.5 +/- 9.5 and 150.1 +/- 9.6 mm Hg in the intervention and control groups, respectively (p=0.22). At 9 months, systolic blood pressure decreased to 124.5 +/- 10.7 and 132.0 +/- 15.1 mm Hg (p=0.0038 between groups), and blood pressure was controlled in 78.5% and 48.7% (p=0.0017) of patients in the intervention and control groups, respectively. By 18 months, systolic blood pressure had deteriorated to 131.0 +/- 12.2 and 143.3 +/- 17.5 mm Hg (p<0.001), and blood pressure control rates decreased to 53.9% and 30.8% (p=0.02). By 27 months, systolic blood pressure was 131.3 +/- 13.0 and 141.2 +/- 15.8 mm Hg (p=0.0008), and blood pressure control was 55.4% and 35.9% (p=0.05).

conclusionA sustained positive effect on blood pressure control was noted up to 18 months after discontinuation of a physician-pharmacist collaborative intervention, when compared with a control group. Blood pressure control did deteriorate at a similar rate in both the intervention and control groups, but the percentage of patients with controlled blood pressure remained significantly higher in the intervention group. These results suggest that continued interventions by pharmacists may be necessary to maintain high rates of blood pressure control, especially in those patients whose blood pressure begins to increase.

Indexed as

Pharmaceutical ServicesAdultAgedAged, 80 and overAntihypertensive AgentsBlood PressureFemaleFollow-Up StudiesHumansHypertensionInterprofessional RelationsMaleMedical RecordsMedication AdherenceMiddle AgedPharmacistsAntihypertensive Agents

Identifiers

PMID20180606
PMCPMC2882166

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.